You are here

CELDARA MEDICAL, LLC

Company Information
Address
16 CAVENDISH CT
LEBANON, NH 03766-1441
United States


http://www.celdaramedical.com

Information

UEI: MMVKQXZUBMQ7

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR Success: Celdara Medical LLC

    How much good could you do with $30 billion dollars and the smartest people in the world? That is the question that the founders of Celdara Medical asked themselves when beginning the company in 2008.Each year, the National Institutes of Health allocates $30 billion to the best and brightest...

Award Charts




Award Listing

  1. A Novel Broad-spectrum Antiviral Agent

    Amount: $590,654.00

    Summary Accelerating emergence and re-emergence of a wide array of viral epidemics has been a deadly feature of the 21st century. Potent or even effective therapies are rarely available to combat thes ...

    STTRPhase I2021Department of Health and Human Services National Institutes of Health
  2. Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas

    Amount: $274,085.00

    PROJECT SUMMARY Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  3. Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus

    Amount: $2,922,162.00

    PROJECT SUMMARY The filoviruses (family Filoviridae), comprising five ebolaviruses, a cuevavirus, and two Marburg viruses, are negative-strand RNA viruses that cause severe hemorrhagic fever with up t ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  4. Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM

    Amount: $1,745,849.00

    Project Summary Acute Kidney Injury (AKI) is common in hospitalized patients after severe illness or following major surgeries, such as cardiovascular surgery. The incidence of AKI in critically ill p ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  5. Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics)

    Amount: $258,360.00

    Project Summary The NIAID has made one of its highest priorities the development of a universal influenza treatment. Current therapeutic strategies for timely neutralization of influenza A virus (IAV) ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  6. Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM)

    Amount: $299,152.00

    Project Summary Type 2 diabetes mellitus (T2DM) is a major unmet public health concern with an annual cost in the United States of over 300 billion dollars, according to the American Diabetes Associat ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  7. SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

    Amount: $599,977.00

    Goal is to develop the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines to provide protection against a wide variety of seasonal and potentially also pandemic flu virus ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  8. Discovery of Parasite-Derived Tolerogenic Adjuvants

    Amount: $599,234.00

    Our goal is to identify novel parasite derived immunomodulatory tolerogenic adjuvants that can suppress pro inflammatory and autoimmune disease statessuch as typediabeteswhich has no disease modifying ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  9. A novel antibody therapy for Sin Nombre virus infection

    Amount: $594,250.00

    Project Summary Rodent-borne viral outbreaks are increasing in both frequency and impact. Hantaviruses are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  10. Cellular Immunotherapy for Systemic Sclerosis

    Amount: $1,480,622.00

    Project Summary Systemic sclerosis (SSc) is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs, vascular dropout and autoantibody formation. SSc has the ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government